NCT03659773

Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

A Prospective Cohort Study of Efficacy, Safety and Characterization of Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Hematopoietic stem cell transplantation (HSCT) is a cellular therapy aiming at curing some hematological diseases. Upon transplantation, recipients experience a phase of profound immune suppression with loss of protective immunity against most infectious agents. Revaccination of HSCT recipients against vaccine-preventable infections is an important post-transplant intervention for reducing morbi-mortality. The VaccHemInf project aims at assessing the efficacy of recommended vaccines in adult recipients of HSCT, through the antibody titers reference method and a panel of immune functional assays.

Conditions

• Vaccination
• Hematopoietic Stem Cells

Interventions

Type	Name	Description
BIOLOGICAL	immune biomarkers to evaluate vaccine response in HSCT recipients	a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study

Timeline

• Start date: 2018-04-27
• Primary completion: 2021-01-21
• Completion: 2023-01-21
• First posted: 2018-09-06
• Last updated: 2025-09-04

Locations

2 sites across 1 country: France